First Department of Internal Medicine, Department of Hematology, Medical University, Plovdiv, Bulgaria.
Clinic of Clinical Hematology, University Hospital "Sv. Georgi", Plovdiv, Bulgaria.
Ann Med. 2020 May-Jun;52(3-4):94-108. doi: 10.1080/07853890.2020.1744708. Epub 2020 Mar 26.
To assess serum sclerostin in transfusion-dependent beta-thalassaemia patients versus healthy controls and to examine its associations with bone mineral density, bone metabolism markers and beta thalassaemia alterations. Sixty-two transfusion-dependent beta-thalassaemia (TDßT) patients and 30 healthy controls were evaluated for serum sclerostin, osteocalcin, beta-cross laps, osteoprotegerin and serum level of receptor activator of nuclear factor kappa-Β ligand (sRANKL). Bone mineral density was measured at the lumbar spine and femoral neck. Thalassaemia characteristics were collected from the patients' medical records. A significantly higher sclerostin level (median 565.50 pmol/L) was observed in the transfusion-dependent beta-thalassaemia patients vs. the healthy controls (median 48.65 pmol/L, < .001). Sclerostin showed significant associations with the Z-scores at the lumbar spine and femoral neck, osteocalcin, beta-cross laps, osteoprotegerin, sRANKL, pretransfusion haemoglobin, liver iron concentration and female gonadal state. Significantly higher levels of sclerostin were observed in splenectomized TDßT patients and in those with fragility fractures. Age, sex, body mass index, disease severity, serum ferritin, cardiac T2* and male gonadal state did not show significant associations with sclerostin. Sclerostin may play a role in the bone pathophysiology of beta-thalassaemia patients and could serve as a marker of severe osteoporosis.KEY MЕSSAGESSerum sclerostin is more than 10-fold higher in adult patients with transfusion-dependent beta-thalassaemia compared to healthy controls.Serum sclerostin is negatively associated with bone mineral density and the bone synthesis markers and positively with the bone resorption indices.Serum sclerostin is significantly associated with pre-transfusion haemoglobin, liver iron concentration, splenectomy status and fragility fracture events in adult patients with transfusion-dependent beta-thalassaemia.Serum sclerostin could serve as a marker of severe osteoporosis in beta-thalassaemia patients.
评估依赖输血的β地中海贫血患者与健康对照者的血清护骨素水平,并探讨其与骨密度、骨代谢标志物和β地中海贫血改变的相关性。
对 62 例依赖输血的β地中海贫血(TDßT)患者和 30 例健康对照者进行血清护骨素、骨钙素、β-胶原降解产物、护骨素和核因子 κB 受体激活剂配体(sRANKL)水平检测,测量腰椎和股骨颈的骨密度。从患者病历中收集地中海贫血特征。
与健康对照组相比,依赖输血的β地中海贫血患者的血清护骨素水平显著升高(中位数 565.50 pmol/L 比 48.65 pmol/L, < .001)。护骨素与腰椎和股骨颈 Z 评分、骨钙素、β-胶原降解产物、护骨素、sRANKL、输血前血红蛋白、肝铁浓度和女性性腺状态显著相关。脾切除术和脆性骨折患者的护骨素水平显著升高。年龄、性别、体重指数、疾病严重程度、血清铁蛋白、心脏 T2*和男性性腺状态与护骨素无显著相关性。
血清护骨素在依赖输血的β地中海贫血患者中高于健康对照组 10 倍以上。血清护骨素与骨密度和骨合成标志物呈负相关,与骨吸收指标呈正相关。血清护骨素与依赖输血的β地中海贫血患者输血前血红蛋白、肝铁浓度、脾切除术状态和脆性骨折事件显著相关。血清护骨素可作为β地中海贫血患者严重骨质疏松的标志物。